{"id":68528,"date":"2026-06-18T23:10:07","date_gmt":"2026-06-18T15:10:07","guid":{"rendered":"https:\/\/flcube.com\/?p=68528"},"modified":"2026-06-18T23:10:09","modified_gmt":"2026-06-18T15:10:09","slug":"eli-lilly-acquires-4e-therapeutics-to-advance-next-generation-chronic-pain-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68528","title":{"rendered":"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced the acquisition of <strong>4E Therapeutics, Inc.<\/strong>, an Austin-based neuroscience company developing <strong>next-generation oral MNK inhibitors<\/strong> for <strong>chronic pain<\/strong> treatment. The transaction strengthens Lilly&#8217;s pain portfolio with a novel approach targeting the <strong>MNK-eIF4E signaling pathway<\/strong> in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly and Company (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>4E Therapeutics, Inc. (private, Austin-based)<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Chronic pain \u2013 next-generation oral therapies<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>4ET1103 \u2013 first MNK inhibitor in human clinical trials for pain<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase I completed with favorable safety profile<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>June 2026<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Acquisition (terms undisclosed)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pipeline-overview-amp-mechanism-of-action\" class=\"wp-block-heading\">Pipeline Overview &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> Oral MNK (MAP kinase-interacting kinase) inhibitors<\/li>\n\n\n\n<li><strong>Target Pathway:<\/strong> <strong>MNK-eIF4E signaling pathway<\/strong> in peripheral sensory neurons<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Peripheral mechanism avoids blood-brain barrier penetration<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> Designed to eliminate CNS-related side effects common with opioids, gabapentinoids, and other current pain therapies<\/li>\n\n\n\n<li><strong>Lead Compound:<\/strong> <strong>4ET1103<\/strong> \u2013 first-in-class MNK inhibitor to enter human clinical trials for pain indication<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-status\" class=\"wp-block-heading\">Clinical Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Stage<\/th><th>Key Results<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>4ET1103<\/strong><\/td><td>Phase I completed<\/td><td>Favorable safety and tolerability profile<\/td><td>First MNK inhibitor in pain clinical development<\/td><\/tr><tr><td><strong>Preclinical Candidates<\/strong><\/td><td>Lead optimization<\/td><td>Promising efficacy in chronic pain models<\/td><td>Multiple backup compounds with improved properties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase I data demonstrated that 4ET1103 achieved target engagement without evidence of central nervous system penetration, supporting the peripheral mechanism hypothesis and potential for improved safety compared to existing analgesics.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic Pain Burden:<\/strong> Affects over 50 million Americans with limited safe, effective long-term treatment options<\/li>\n\n\n\n<li><strong>Opioid Crisis Response:<\/strong> Addresses urgent need for non-addictive, non-CNS-penetrating pain therapies<\/li>\n\n\n\n<li><strong>Market Gap:<\/strong> Current oral analgesics often limited by CNS side effects (sedation, cognitive impairment, addiction potential)<\/li>\n\n\n\n<li><strong>Lilly&#8217;s Pain Portfolio:<\/strong> Complements existing neuroscience pipeline and expands beyond migraine franchise<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Oral administration suitable for primary care setting with broad patient applicability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-differentiation\" class=\"wp-block-heading\">Competitive Landscape &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism Uniqueness:<\/strong> First clinical-stage program specifically targeting MNK-eIF4E pathway for pain<\/li>\n\n\n\n<li><strong>Peripheral Targeting:<\/strong> Unlike most analgesics that act centrally, 4E&#8217;s approach focuses on pain signal generation at source<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Potential to avoid common side effects including drowsiness, dizziness, cognitive impairment, and addiction risk<\/li>\n\n\n\n<li><strong>Oral Bioavailability:<\/strong> Convenient dosing compared to injectable biologics in development for pain<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The acquisition provides Lilly with a differentiated late-preclinical\/early-clinical asset addressing one of healthcare&#8217;s most persistent challenges: safe, effective chronic pain management without CNS-related complications.<\/p>\n\n\n\n<h2 id=\"h-development-strategy-amp-timeline\" class=\"wp-block-heading\">Development Strategy &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Next Milestone:<\/strong> Phase II clinical trials expected to initiate in H2 2026<\/li>\n\n\n\n<li><strong>Indication Focus:<\/strong> Initial development in neuropathic pain and inflammatory pain conditions<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Potential for expedited development given unmet medical need and novel mechanism<\/li>\n\n\n\n<li><strong>Commercial Preparation:<\/strong> Leveraging Lilly&#8217;s established pain commercial infrastructure and primary care relationships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial potential. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4815,199,911],"class_list":["post-68528","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-4e-therapeutics","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based neuroscience company developing next-generation oral MNK inhibitors for chronic pain treatment. The transaction strengthens Lilly&#039;s pain portfolio with a novel approach targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68528\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based neuroscience company developing next-generation oral MNK inhibitors for chronic pain treatment. The transaction strengthens Lilly&#039;s pain portfolio with a novel approach targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68528\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T15:10:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-18T15:10:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68528#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68528\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline\",\"datePublished\":\"2026-06-18T15:10:07+00:00\",\"dateModified\":\"2026-06-18T15:10:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68528\"},\"wordCount\":509,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"4E Therapeutics\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68528#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68528\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68528\",\"name\":\"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-18T15:10:07+00:00\",\"dateModified\":\"2026-06-18T15:10:09+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based neuroscience company developing next-generation oral MNK inhibitors for chronic pain treatment. The transaction strengthens Lilly's pain portfolio with a novel approach targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68528#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68528\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68528#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based neuroscience company developing next-generation oral MNK inhibitors for chronic pain treatment. The transaction strengthens Lilly's pain portfolio with a novel approach targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68528","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline","og_description":"Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based neuroscience company developing next-generation oral MNK inhibitors for chronic pain treatment. The transaction strengthens Lilly's pain portfolio with a novel approach targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.","og_url":"https:\/\/flcube.com\/?p=68528","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-18T15:10:07+00:00","article_modified_time":"2026-06-18T15:10:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68528#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68528"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline","datePublished":"2026-06-18T15:10:07+00:00","dateModified":"2026-06-18T15:10:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68528"},"wordCount":509,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["4E Therapeutics","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68528#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68528","url":"https:\/\/flcube.com\/?p=68528","name":"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-18T15:10:07+00:00","dateModified":"2026-06-18T15:10:09+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced the acquisition of 4E Therapeutics, Inc., an Austin-based neuroscience company developing next-generation oral MNK inhibitors for chronic pain treatment. The transaction strengthens Lilly's pain portfolio with a novel approach targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons, designed to provide effective pain relief while avoiding central nervous system side effects.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68528#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68528"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68528#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68528"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68528\/revisions"}],"predecessor-version":[{"id":68529,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68528\/revisions\/68529"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}